SCHEMBL24978417

SCHEMBL24978417

CC(C)(O)c1ccc(S(=O)(=O)N[Si](C)(C)C(C)(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
MEN1 O00255 2/20 0.43
MAPT P10636 2/20 0.43
KMT2A Q03164 2/20 0.43
UQCRB P14927 3/20 0.43
HSD11B1 P28845 1/20 0.43
POLB P06746 2/20 0.42
HTT P42858 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
RORA P35398 1/20 0.42
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
HDAC3 O15379 2/20 0.39
HDAC11 Q96DB2 2/20 0.39
HDAC8 Q9BY41 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
NR3C2 P08235 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22012922 0.83 PSEN1 (0.32) ALDH1A1MEN1MAPTKMT2AUQCRB
SCHEMBL22012887 0.82 ABCC9 (0.36) ALDH1A1MEN1MAPTKMT2AUQCRB
SCHEMBL25067022 0.81 NLRP3 (0.46) ALDH1A1MEN1MAPTKMT2AUQCRB
SCHEMBL21971206 0.81 GAA (0.52) ALDH1A1MEN1MAPTKMT2APOLB
SCHEMBL20681168 0.81 ALDH1A1 (0.41) ALDH1A1MEN1MAPTKMT2AUQCRB
SCHEMBL20680960 0.81 ALDH1A1 (0.41) ALDH1A1MEN1MAPTKMT2AUQCRB
SCHEMBL25031496 0.80 ALDH1A1 (0.42) ALDH1A1MEN1MAPTKMT2AUQCRB
SCHEMBL23851285 0.80 KMT2A (0.54) ALDH1A1MAPTKMT2AHTTSMN1; SMN2
SCHEMBL22012109 0.80 PIK3R1 (0.34) ALDH1A1POLBHTTSMN1; SMN2CYP3A4
SCHEMBL10680402 0.79 KEAP1 (0.48) ALDH1A1MEN1KMT2APOLBCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111094242-B Compounds and compositions for treating disorders associated with NLRP activity 诺华股份有限公司 2024-02-09 CN disclosed
US-20230031406-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2023-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230031406-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NLRP1, NLRP3, NOD1 ALDH1A1 1972/4885MEN1 3390/4885MAPT 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.